Management of Extraocular Retinoblastoma: ICMR Consensus Guidelines.
Chemotherapy
Extraocular
Radiotherapy
Retinoblastoma
Journal
Indian journal of pediatrics
ISSN: 0973-7693
Titre abrégé: Indian J Pediatr
Pays: India
ID NLM: 0417442
Informations de publication
Date de publication:
19 Apr 2024
19 Apr 2024
Historique:
received:
23
01
2024
accepted:
13
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
aheadofprint
Résumé
Retinoblastoma (RB) is the most common intraocular malignancy of childhood. Advanced stage presentation of RB is common in low middle-income countries (LMICs) due to lack of awareness, social taboos associated with enucleation, seeking alternative conservative treatment options, and poor accessibility to health care. Over the last few decades, there have been significant advancements in the management of extraocular RB (EORB) which have improved outcomes and helped in minimizing treatment-related toxicities. The incorporation of multimodality approaches including chemotherapy, surgery, and radiotherapy (RT) has shown promising results; however, prognosis remains poor especially in LMICs. In this article, authors have discussed the ICMR consensus guidelines on the management of EORB, including metastatic RB.
Identifiants
pubmed: 38639859
doi: 10.1007/s12098-024-05104-2
pii: 10.1007/s12098-024-05104-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.
Références
Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93:1129–31.
pubmed: 19704035
doi: 10.1136/bjo.2008.150292
Chantada G, Doz F, Antoneli CBG, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47:801–5.
pubmed: 16358310
doi: 10.1002/pbc.20606
Fabian ID, Abdallah E, Addullahi SU, et al; Global Retinoblastoma Study Group. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020;6:685–95.
pubmed: 32105305
doi: 10.1001/jamaoncol.2019.6716
Malhotra RK, Manoharan N, Nair O, Deo SVS, Bakhshi S, Rath GK. Patterns and trends of childhood cancer incidence (0–14 years) in Delhi, India: 1990–2014. Indian Pediatr. 2021;58:430–5.
pubmed: 33980729
doi: 10.1007/s13312-021-2212-8
Bakhshi S, Gupta S, Gogia V, Ravindranath Y. Compliance in retinoblastoma. Indian J Pediatr. 2010;77:535–40.
pubmed: 20422323
doi: 10.1007/s12098-010-0047-8
Indian Council of Medical Research. Consensus Document for Management of Retinoblastoma. 2023:1–73. Available at: https://main.icmr.nic.in/sites/default/files/upload_documents/RB_Document.pdf .
Radhakrishnan V, Sharma S, Vishnubhatla S, Bakhshi S. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). Br J Ophthalmol. 2013;97:52–8.
pubmed: 23117972
doi: 10.1136/bjophthalmol-2012-301977
Chiranthan M, Meel R, Bakhshi S, et al. Baseline and post-NACT imaging in retinoblastoma with optic nerve involvement: can MRI predict prognosis? J Pediatr Ophthalmol Strabismus. 2023. https://doi.org/10.3928/01913913-20230714-01 .
doi: 10.3928/01913913-20230714-01
pubmed: 37615419
Wiwatwongwana D, Kulniwatcharoen P, Mahanupab P, Visrutaratna P, Wiwatwongwana A. Accuracy of computed tomography and magnetic resonance imaging for detection of pathologic risk factors in patients diagnosed with retinoblastoma. Curr Eye Res. 2021;46:1544–50.
pubmed: 33752572
doi: 10.1080/02713683.2021.1901938
Cho SJ, Kim JH, Baik SH, Sunwoo L, Bae YJ, Choi BS. Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: a systematic review and meta-analysis. Neuroradiology. 2021;63:499–509.
pubmed: 32865636
doi: 10.1007/s00234-020-02538-1
Bakhshi S, Meel R, Kashyap S, Sharma S. Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlation with IRSS staging. J Pediatr Hematol Oncol. 2011;33:e182–5.
pubmed: 21364467
doi: 10.1097/MPH.0b013e3182103f5c
Radhakrishnan V, Kumar R, Malhotra A, Bakhshi S. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. J Nucl Med. 2012;53:191–8.
pubmed: 22251556
doi: 10.2967/jnumed.111.095836
Gündüz K, Müftüoglu O, Günalp I, Unal E, Taçyildiz N. Metastatic retinoblastoma: clinical features, treatment and prognosis. Ophthalmology. 2006;113:1558–66.
pubmed: 16828510
doi: 10.1016/j.ophtha.2006.03.039
Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40:158–61.
pubmed: 12518344
doi: 10.1002/mpo.10249
Antoneli CBG, Steinhorst F, de Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98:1292–8.
pubmed: 12973854
doi: 10.1002/cncr.11647
Antoneli CBG, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cispla-tin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29:700–4.
pubmed: 17921851
doi: 10.1097/MPH.0b013e31814fb7ea
Radhakrishnan V, Kashyap S, Pushker N, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology. 2012;119:1470–7.
pubmed: 22463820
doi: 10.1016/j.ophtha.2012.01.029
Meel R, Bakhshi S, Pushker N, Vishnubhatia S. Randomized, controlled trial in groups C and D retinoblastoma. Ophthalmology. 2015;122:433–5.
pubmed: 25439612
doi: 10.1016/j.ophtha.2014.09.013
Jaradat I, Mubiden R, Salem A, Abdel-Rahman F, Al-Ahmad I, Almousa A. High-dose chemotherapy followed by stem cell transplantation in the management of retinoblastoma: a systematic review. Hematol Oncol Stem Cell Ther. 2012;5:107–17.
pubmed: 22828375
doi: 10.5144/1658-3876.2012.107
Dunkel IJ, Chan HSL, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55:149–52.
pubmed: 20486181
doi: 10.1002/pbc.22491
Rodriguez A, Zugbi S, Requejo F, et al. Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma. Pediatr Blood Cancer. 2018;65:e27385.
pubmed: 30105793
doi: 10.1002/pbc.27385
Hu H, Zhang W, Wang Y, et al. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC Ophthalmol. 2018;18:107.
pubmed: 29685116
pmcid: 5914066
doi: 10.1186/s12886-018-0772-8
Chantada GL, Dunkel IJ, de Dávila MTG, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069–73.
pubmed: 15258027
pmcid: 1772257
doi: 10.1136/bjo.2003.037044
Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122:1316–23.
pubmed: 15364710
doi: 10.1001/archopht.122.9.1316
Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923–31.
pubmed: 12096963
doi: 10.1001/archopht.120.7.923
Singh U, Katoch D, Kaur S, Dogra MR, Bansal D, Kapoor R. Retinoblastoma: a sixteen-year review of the presentation, treatment, and outcome from a tertiary care institute in northern India. Ocul Oncol Pathol. 2017;4:23–32.
pubmed: 29344495
pmcid: 5757564
doi: 10.1159/000477408
Pérez V, Sampor C, Rey G, et al. Treatment of nonmetastatic unilateral retinoblastoma in children. JAMA Ophthalmol. 2018;136:747–52.
pubmed: 29799944
pmcid: 6136048
doi: 10.1001/jamaophthalmol.2018.1501
Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31:1458–63.
pubmed: 23460706
doi: 10.1200/JCO.2012.42.3962
Foote RL, Garretson BR, Schomberg PJ, Buskirk SJ, Robertson DM, Earle JD. External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis. Int J Radiat Oncol Biol Phys. 1989;16:823–30.
pubmed: 2493436
doi: 10.1016/0360-3016(89)90502-6
Abramson DH, Frank CM. Second non-ocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573–9.
pubmed: 9544627
doi: 10.1016/S0161-6420(98)94006-4
Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35:763–6.
pubmed: 15750608
doi: 10.1038/sj.bmt.1704882
Dunkel IJ, Piao J, Chantada GL, et al. Intensive multimodality therapy for extraocular retinoblastoma: A Children’s Oncology Group Trial (ARET0321). J Clin Oncol. 2022;40:3839–47.
pubmed: 35820112
pmcid: 9671757
doi: 10.1200/JCO.21.02337
Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology. 2003;110:1237–40.
pubmed: 12799253
doi: 10.1016/S0161-6420(03)00258-6
Tsang DS, Vargo JA, Goddard K, Breneman JC, Kalapurakal JA, Marcus KJ. Palliative radiation therapy for children with cancer. Pediatr Blood Cancer. 2021;68:e28292.
pubmed: 33818881
doi: 10.1002/pbc.28292
Kim JW, Kathpalia V, Dunkel IJ, Wong RK, Riedel E, Abramson DH. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol. 2009;93:463–7.
pubmed: 18757474
doi: 10.1136/bjo.2008.138453
Brennan RC, Qaddoumi I, Mao S, et al. Ocular salvage and vision preservation using a topotecan-based regimen for advanced intraocular retinoblastoma. J Clin Oncol. 2017;35:72–7.
pubmed: 28034080
doi: 10.1200/JCO.2016.69.2996
Pramanik R, Bakhshi S. Metronomic therapy in pediatric oncology: a snapshot. Pediatr Blood Cancer. 2019;66:e27811.
pubmed: 31207063
doi: 10.1002/pbc.27811
Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. Indian J Pediatr. 2012;79:1617–22.
pubmed: 22544675
doi: 10.1007/s12098-012-0759-z
Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol. 2017;3:1222–7.
pubmed: 28384657
pmcid: 5824286
doi: 10.1001/jamaoncol.2017.0324
Kumar K, Radhakrishnan V, Dhanushkodi M, et al. Oral etoposide and cyclophosphamide: a low-cost palliative metronomic chemotherapy in advanced pediatric cancers. Cancer Res Stat Treat. 2020;3:64–8.
doi: 10.4103/CRST.CRST_90_19
Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.
pubmed: 10561222
doi: 10.1200/JCO.1999.17.6.1829
de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivelä T, Moll AC. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1157–67.
pubmed: 25126964
doi: 10.1016/S1470-2045(14)70336-5
Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100:1771–9.
pubmed: 19066271
doi: 10.1093/jnci/djn394
Batra A, Kain R, Kumari M, Paul R, Dhawan D, Bakhshi S. Parents’ perspective of quality of life of retinoblastoma survivors. Pediatr Blood Cancer. 2016;63:1287–9.
pubmed: 27038275
doi: 10.1002/pbc.25982
Batra A, Thakar A, Bakhshi S. Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: a cross-sectional study of 116 patients. Pediatr Blood Cancer. 2015;62:2060.
pubmed: 26053139
doi: 10.1002/pbc.25618